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ABSTRACT 
 
Most glaucoma drugs lower the intraocular pressure (IOP) by decreasing the aqueous humor production and in-
creasing the outflow through uveoscleral pathway. None of these drugs work mainly on increasing outflow through 
the trabecular pathway. Consequently, the experiment to develop glaucoma drugs directly target at the trabecular 
outflow pathway is highly required. The purpose of this study is to reveal the effect of rho-kinase inhibitor Y-27632 
on the thickness of trabecular meshwork in juvenile rats model injected with sodium hyaluronate.  This study was 
an experimental study with posttest only control group design. Twenty-four rats were included in this study. Each 
eye of the rat would be considered as one sample. Samples were divided into 6 groups, negative control group, 
positive control I group with intracameral sodium hyaluronate injection, positive control II group with topical Y-
27632 10 mM, and three experimental groups with intracameral injection of sodium hyaluronate and Y-27632 10-1 
mM, 1 mM, and 10 mM respectively. After the procedures all rats were sacrificed and enucleated. Trabecular mesh-
work tissue was stained with Hematoxilene-Eosin and evaluated under 400× microscopic magnification. Quantitative 
measurements were taken using computerized image analysis with dot slide program.  There were significant statistic 
differences among the positive control I group and the experimental groups (p-value < 0.05) as well as the positive 
control II group and the experimental groups (p-value < 0.05). The highest mean of decreasing trabecular meshwork 
thickness was noted in the group given by sodium hyaluronate and Y-27632 10 mM with value of 118.42 µm. There 
was decreasing thickness of trabecular meshwork due to the effect of rho- kinase inhibitor Y-27632 in juvenile rats 
injected with sodium hyaluronate. 
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INTRODUCTION 
Primary open angle glaucoma (POAG) is one of the 
leading cause of visual impairment worldwide. In most 
cases the aqueous humor secretion remains normal in 
glaucoma and the main risk factors related to the disease 
are the elevation of Intraocular Pressure (IOP) and high 
levels of aqueous humor outflow resistance. Despite the 
precise underlying mechanism regarding the increasing 
outflow resistance in POAG remains unclear, most con-
sensus stated that the basic resistance located in trabec-
ular meshwork (TM) outflow pathway. Presently, most 
glaucoma medications decrease the IOP by targeting the 
aqueous humor formation and uveoscleral pathway re- 
sistance. Even so, none of the first line medication ther-
apy option obtainable for patients with trabecular mesh-
work outflow pathway resistance. There are three im-
portant structures of the trabecular meshwork related to 
aqueous humor outflow regulation, extracellular matrix 
in the juxtacanalicular region, inner wall of Schlemm’s 
canal and its lumen [1, 2, 3]. 
Rho-kinase protein is one of those proteins which 
maintain the physiologic function of trabecular mesh-
work. It contributes in regulating actomyosin organiza-
tion and extracellular matrix synthesis. The modulation 
of this system will interfere the changes in volume, con-
tractility, and adhesion of trabecular meshwork cell. 
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Rho-kinase specific inhibitor has been shown to induce 
inhibition of actomyosin activity and modulate the tra-
becular meshwork and Schlemm’s canal morphology. Y-
27632 is noted as one of those protein inhibitors. Honjo 
(2001) concluded that Y-27632 had reduced the intraoc-
ular pressure significantly in rabbits. Cellular changes of 
trabecular meshwork and ciliary muscle relaxation were 
considered to be the underlying mechanism [4, 5, 6]. 
Y-27632 has been used widely in experimental re-
search both in vivo and in vitro in adults. This fact en-
courages our study to evaluate the morphology of tra-
becular meshwork in juvenile age. Benozzi (2002) stated 
that sodium hyaluronate injection had increased the 
density of extracellular matrix and decreased the diame-
ter of flow channels [7]. 
The purpose of this study is to evaluate the effect of 
rho-kinase inhibitor (Y-27632) on trabecular meshwork 
thickness in juvenile rat model with sodium hyaluronate 
injection. 
 
MATERIALS AND METHOD 
Animals sampling 
This study was conducted in Physiology Laboratory 
of Faculty of Medicine Universitas Brawijaya Malang 
from July 2012 to October 2012. Twenty-four juvenile 
Wistar rats aged 4 – 6 weeks with 100 ± 50 gr in weight 
were included in this study.  
 
Preparation of the eyes 
Samples were divided into six groups, first group as 
negative control without any treatment, second group as 
positive control I group received only intracameral 
sodium hyaluronate injection, and third to fifth groups 
given intracameral sodium hyaluronate injection and 
topical rho-kinase inhibitor (Y-27632) with concentra-
tion of 0.1 mM, 1 mM, and 10 mM respectively. The 
sixth group considered as positive control II group re-
ceived only topical rho-kinase inhibitor (Y-27632) with 
10 mM concentration. The second to fifth group were 
anesthetized with ketamine hydrochloride (50 mg/kg) 
(Ketamine-hameln 50 mg/mL, Hameln pharmaceuti-
cals, Germany) administered intraperitoneally. Fifteen 
µL of sodium hyaluronate (BBTVisc 1.5%, Bohus Bio-
Tech) was injected into one eye of anesthe-tized rats us-
ing a syringe and a 30-gauge needle. The eyes were fo-
cused under a surgical microscope (DECA-21, Inami & 
Co.Ltd, Model-0940SD, made in Japan) with coaxial 
light. The needle moved through the corneoscleral lim-
bus to the anterior chamber with the bevel down. When 
the tip of the bevel reached the anterior chamber, the 
liquid progressively increased the chamber’s depth, sep-
arating the needle from the iris and avoiding needle–
lens contact. Applications were made slowly but using a 
force sufficient to just empty the syringe content. 
Antibiotic eye ointment was applied after injection. 
Application of 1 drop of 0.5% proparacaine hydro-
chloride were performed 24 hours later on each eye. The 
second group was then received no other treatment. The 
third to fifth group were given topical rho-kinase inhib-
itor (Y-27632) with concentration of 0.1 mM, 1 mM, dan 
10 mM respectively. Each treatment was administered to 
the central cornea as four 3-ml drops at intervals of 30 
seconds, with blinking prevented between and after the 
last drops. The sixth group was only treated with Y-
27632 10 mM topically. All animals were sacri-ficed 3 
hours after treatment. 
Eyes were enucleated immediately after sacrificing, 
then subdivided at the equator into an anterior and pos-
terior segment. The eyes were fixed in 4% parafor-mal-
dehyde (PFA). The anterior segments were subdi-vided 
into quadrants after careful removal of the lens. From all 
quadrants 1 – 2 mm wide specimens including trabecu-
lar meshwork and Schlemm’s canal were pre-pared and 
the specimens were embedded in paraffin. 
 
Histological analysis 
The specimens were stained with Hematoxilene-eo-
sin and histologically analyzed using light microscopic 
with 400× magnification. Photographs of the micros-
copic sections were taken and analyzed using automated 
image and dot slide program. In the meridional sections, 
measurements were taken of the thickness of the trabec-
ular meshwork. Measurements were taken four times 
and the average value was stated in µm. 
 
Statistics 
Data were analyzed using independent t-tests, one-
way ANOVA, and multiple comparison test with Least 
Significance Difference (LSD). P-value < 0.05 was con-
sidered to be statistically significant. 
 
RESULTS AND DISCUSSION 
Trabecular meshwork appeared as a fenestrated tis-
sue containing multilayer lamella and endothelial cells. 
The appearance of trabecular meshwork in control 
groups and the decreasing thickness of trabecular mesh-
work along with the increasing concentration of rho-ki-
nase inhibitor (Y-27632) were seen in Figure 1. 
The trabecular meshwork thickness was measured 
after the paraffin process of the tissue and HE staining  
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Figure 1. Trabecular meshwork thickness (arrows) in HE stain-
ing under 400× microscopic magnification (Note: A. 
Negative control group. B. Positive control I group. C. 
Positive control II group. D. Y-27632 10-1 mM group. 
E. Y-27632 1mM group. F. Y-27632 10mM group) 
 
Table 1. The average of trabecular meshwork thickness in all 
groups 
Group Mean ± SD(µm) 
Control (-) 
Control (+) I 
Control (+) II 
10-1 mM Y-27632 
1 mM Y-27632 
10 mM Y-27632 
61.03 ± 2.23 
65.73 ± 1.11 
57.68 ± 0.54 
53.85 ± 0.97 
46.24 ± 1.18 
41.25 ± 1.94 
 
The average of trabecular meshwork thickness in all 
groups were stated in Table 1. 
One-way ANOVA test showed the differences of 
trabecular meshwork thickness among positive I control 
group and treatment groups (p < 0.05). The results were 
then analyzed using LSD as multiple comparisons test 
and the significant differences among all groups were 
noted (p < 0.05) (Table 2). 
One-way ANOVA test showed the differences of trabec-
ular meshwork thickness among positive control II 
group and treatment groups (p < 0.05). The results were 
then analyzed using LSD as multiple comparisons test 
and the significant differences among all groups were 
noted (p < 0.05) (Table 3). 
Table 2. Results of LSD test between positive I control group 
and treatment groups  
Variables Comparison groups p-value 
Trabecular 
Meshwork 
Thickness 
10-1 mM Y-27632 1 mM Y-27632 0 
 10 mM Y-27632 0 
1 mM Y-27632 Control (+) I 0 
 10 mM Y-27632 0.001 
10 mM Y-27632 Control (+) I 0 
 Control (+) I 0 
 
Table 3. Results of LSD test between positive control ii group 
and treatment groups 
Variables Comparison groups p-value 
Trabecular 
Meshwork 
Thickness 
10-1 mM Y-27632 1 mM Y-27632 0 
 10 mM Y-27632 0.003 
1 mM Y-27632 Control (+) I 0 
 10 mM Y-27632 0 
10 mM Y-27632 Control (+) I 0 
 Control (+) I 0 
In this study, measurements were performed using 
a computerized dot-slide program and done by one ob-
server repeated 4 times and then taken on average in 
every sample. Instrumentation in a reliable and objective 
measurement would provide a good internal validity. 
Randomization was also performed on sample selection 
so that all rats in this study were drawn at random ac-
cording to the inclusion criteria. There were no samples 
that died or were excluded from this study. The exist-
ence of mortality or drop out sample will reduce the in-
ternal validity of the study. The use of control groups in 
experimental research will support the external validity. 
There were two positive control groups and one negative 
control group used in this study. Given all the reasoning 
above it might be assumed that the validity of the re-
search is quite good. 
Trabecular meshwork tissue is recognized to have 
the highest responsibility in regulating aqueous humor 
outflow as conventional pathway. Trabecular meshwork 
consists of three zones, the uveal meshwork, corneoscle-
ral meshwork, and juxtacanalicular connective tissue. 
Trabecular meshwork tissue is considered to obtain reg-
ulatory mechanism as it also has smooth-muscle-like 
properties. The actomyosin system has contributed to 
the regulation of contraction as well as relaxation of the 
tissue [8]. 
Rho-kinase is identified to be involved in various 
physiological roles in correlation with cytoskeletal sys-
tem such as the cell morphology, motility, and smooth 
muscle contraction. This protein is also expressed in the 
a d 
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trabecular meshwork tissue. Y-27632 is currently identi-
fied as specific inhibitor of the rho-protein kinase [9]. 
The concentration of Y-27632 used in this study 
based on the previous experiment. Honjo (2001) con-
ducted the study with Y-27632 chosen concentration of 
10 and 100 mM to provide the desired concentration 
with assumption that only 1% of the drug penetrated 
intracamerally in approximately 125 µL rabbit anterior 
chamber volume. As much as 15 µL anterior chamber 
volume in rats were included in this study therefore we 
used 1/10 concentration of the previous study concentra-
tion [6]. 
The increasing intraocular pressure effect caused by 
sodium hyaluronate injection were noted after 24 hours 
and lasted for 5 days in the study conducted by Benozzi 
(2002). We also used the same 24 hours after injection 
to perform topical application of Y-27632. Honjo (2001) 
also stated that Y-27632 decreased the intraocular pres-
sure after 30 minutes and reached the peak after 1 to 3 
hours of application. In this study the evaluation was 
conducted after 3 hours of Y-27632 administration in 
order to gain optimal effect [6, 7]. 
The lowest average thickness of the trabecular 
meshwork was noted in the group receiving Y-27632 10 
mM. Zhang (2008) stated that trabecular meshwork has 
components that resemble smooth muscle cells and 
other proteins related to cytoskeletal processes. Giving 
agents that cause an increase in actin depolymerization 
and decreased the interactions among cells in the trabec-
ular meshwork may induce relaxation of the trabecular 
meshwork so that the tissue is reduced in thickness. Rao 
(2001) stated that the Y-27632 increased permeability 
and changes in cell adhesion as well as relaxation of the 
trabecular meshwork. Germano (2015) identified that 
the precise mechanism of Rho-kinase inhibitor in in-
creasing the conventional outflow of aqueous humor is 
not utterly understood. It was assumed that the cytoskel-
eton system is disturbed by the inhibition of rho-kinase 
activity. The main effect of this process would be the 
reducing of trabecular meshwork contractility that lead 
to the improvement of aqueous humor outflow [8, 10, 
11]. 
There were significant differences among the 
groups treated with various concentrations of Y-27632 
and the control groups. The data showed that the con-
centration range of Y-27632 have given enough morpho-
logical changes with significant difference. The most 
substantial changes found in the group receiving Y-
27632 with the highest concentration of 10 mM. 
We may conclude from this study that there was a 
tendency of a greater morphological changes of trabec-
ular meshwork along with the increasing concentration 
of Y-27632 given. However, we might not be able to de-
termine the amount of optimal concentration of Y-27632 
to provide the most effective morphological changes of 
trabecular meshwork. It might be affected by the 
changes that were increased linearly in a row with the 
increasing concentration given. So further research is 
still needed with higher concentration and various range 
in order to evaluate the effectiveness of optimal concen-
tration of Y-27632 to morphological changes in the tra-
becular meshwork. The mechanism of trabecular mesh-
work morphological changes due to administration of Y-
27632 are not directly evaluated in this study. This is 
because the research has not included the evaluation of 
molecular changes yet. However, some related re-
searches might have explained the possible underlying 
mechanisms. It is expected that this study is able to be a 
basic research for further evaluation of molecular 
changes in the trabecular meshwork due to Y-27632. 
  
CONCLUSION 
It can be concluded from this study that the admin-
istration of rho-kinase inhibitor (Y-27632) on juvenile 
rats model injected with sodium hyaluronate had re-
sulted in the decreasing thickness of trabecular mesh-
work. We hoped that this agent might be an alternative 
medical therapy in lowering intraocular pressure related 
to the aqueous humor facilitation through the trabecular 
meshwork modulation. Further research is needed to 
evaluate the effectiveness of rho-kinase inhibitor (Y-
27632) on the role of trabecular meshwork modulation 
in molecular basis. 
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